Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $1.46 billion. The enterprise value is $941.83 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 63.75 million shares outstanding. The number of shares has increased by 29.55% in one year.
| Current Share Class | 63.75M |
| Shares Outstanding | 63.75M |
| Shares Change (YoY) | +29.55% |
| Shares Change (QoQ) | +10.56% |
| Owned by Insiders (%) | 0.85% |
| Owned by Institutions (%) | 92.45% |
| Float | 50.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.93 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.67, with a Debt / Equity ratio of 0.09.
| Current Ratio | 25.67 |
| Quick Ratio | 25.41 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.92 |
Financial Efficiency
Return on equity (ROE) is -44.83% and return on invested capital (ROIC) is -26.55%.
| Return on Equity (ROE) | -44.83% |
| Return on Assets (ROA) | -25.14% |
| Return on Invested Capital (ROIC) | -26.55% |
| Return on Capital Employed (ROCE) | -26.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.36M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.39% in the last 52 weeks. The beta is 1.16, so VERA's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -46.39% |
| 50-Day Moving Average | 30.84 |
| 200-Day Moving Average | 38.09 |
| Relative Strength Index (RSI) | 25.58 |
| Average Volume (20 Days) | 744,764 |
Short Selling Information
The latest short interest is 7.25 million, so 11.37% of the outstanding shares have been sold short.
| Short Interest | 7.25M |
| Short Previous Month | 7.80M |
| Short % of Shares Out | 11.37% |
| Short % of Float | 14.34% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -167.17M |
| Pretax Income | -107.85M |
| Net Income | -152.15M |
| EBITDA | -167.07M |
| EBIT | -167.17M |
| Earnings Per Share (EPS) | -$2.75 |
Full Income StatementBalance Sheet
The company has $640.85 million in cash and $54.64 million in debt, giving a net cash position of $586.21 million or $9.20 per share.
| Cash & Cash Equivalents | 640.85M |
| Total Debt | 54.64M |
| Net Cash | 586.21M |
| Net Cash Per Share | $9.20 |
| Equity (Book Value) | 577.16M |
| Book Value Per Share | 9.08 |
| Working Capital | 625.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$134.68 million and capital expenditures -$972,000, giving a free cash flow of -$135.65 million.
| Operating Cash Flow | -134.68M |
| Capital Expenditures | -972,000 |
| Free Cash Flow | -135.65M |
| FCF Per Share | -$2.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |